SPIRIT-P1: Ixekizumab suitable for long-term treatment of psoriatic arthritis
17 Mar 2020
byJairia Dela Cruz
Ixekizumab induces early and durable improvements in psoriatic arthritis (PsA) patients naïve to biological disease-modifying antirheumatic drugs (bDMARDs), with response occurring as early as week 1 and persisting throughout 3 years of treatment without incremental safety risks, according to the results of the phase III SPIRIT-P1* trial.